These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32909675)

  • 1. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
    Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
    Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition.
    Seridi L; Cesaroni M; Orillion A; Schreiter J; Chevrier M; Marciniak S; Migone TS; Stohl W; Chatham WW; Furie RA; Benson J; Jordan J
    Lupus; 2021 Apr; 30(5):795-806. PubMed ID: 33626969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.
    Chatham WW; Furie R; Saxena A; Brohawn P; Schwetje E; Abreu G; Tummala R
    Arthritis Rheumatol; 2021 May; 73(5):816-825. PubMed ID: 33225631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE).
    Oke V; Brauner S; Larsson A; Gustafsson J; Zickert A; Gunnarsson I; Svenungsson E
    Arthritis Res Ther; 2017 Jun; 19(1):139. PubMed ID: 28619037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus.
    Enocsson H; Wetterö J; Eloranta ML; Gullstrand B; Svanberg C; Larsson M; Bengtsson AA; Rönnblom L; Sjöwall C
    Front Immunol; 2021; 12():688753. PubMed ID: 34276678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.
    Hasni S; Gupta S; Davis M; Poncio E; Temesgen-Oyelakin Y; Joyal E; Fike A; Manna Z; Auh S; Shi Y; Chan D; Carlucci P; Biehl A; Dema B; Charles N; Balow JE; Waldman M; Siegel RM; Kaplan MJ; Rivera J
    Arthritis Rheumatol; 2019 Jul; 71(7):1135-1140. PubMed ID: 30597768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z; Cheng R; Liu Y
    Front Immunol; 2022; 13():996662. PubMed ID: 36211347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
    Slight-Webb S; Lu R; Ritterhouse LL; Munroe ME; Maecker HT; Fathman CG; Utz PJ; Merrill JT; Guthridge JM; James JA
    Arthritis Rheumatol; 2016 Oct; 68(10):2492-502. PubMed ID: 27059145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.
    Gensous N; Lazaro E; Blanco P; Richez C
    Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort.
    Willis R; Seif AM; McGwin G; Martinez-Martinez LA; González EB; Dang N; Papalardo E; Liu J; Vilá LM; Reveille JD; Alarcón GS; Pierangeli SS
    Lupus; 2012 Jul; 21(8):830-5. PubMed ID: 22343096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers.
    Chasset F; Ribi C; Trendelenburg M; Huynh-Do U; Roux-Lombard P; Courvoisier DS; Chizzolini C;
    Rheumatology (Oxford); 2020 Nov; 59(11):3468-3478. PubMed ID: 32375176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.